PMA P010029S001
- Device
- NUXFLEXXA (SODIUM HYALURONATE)
- Applicant
- Ferring Pharmaceuticals, Inc.
- PMA number
- P010029
- Supplement
- S001
- Product code
- MOZ
- Decision date
- 2006-02-27
- Classification
- Acid, Hyaluronic, Intraarticular
- Generic name
- Acid, hyaluronic, intraarticular
- Approval order statement
- APPROVAL FOR 1) CHANGING THE STORAGE CONDITIONS SPECIFIED IN THE PRODUCT LABELING FROM, ?STORE IN A COLD DARK PLACE [2 ? 8 DEGREES C (36-46 DEGREES F)]. PROTECT FROM LIGHT. DO NOT FREEZE?. 2) CHANGE THE SPECIFIED SHELF LIFE TIME IN THE LABELING FORM 3 YEARS (AT REFRIGERATED TEMPERATURES) TO 12 MONTHS. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME EUFLEXXA AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN.)
- Summary
- <a href="#main" target="_new">Quick Links: Skip to main page content</a> <a href="#search_form" target="_new">Skip to Search</a> <a href="#fda-topmenu-home" target="_new">Skip to Topics Menu</a> <a href="#footer" target="_new">Skip to Common Links</a> <a href="#" target="_new"><img src="/scripts/includes/images/img_fdagov_font_adj_small.png" alt="Decrease font size" title="Decrease font size"/></a> <a href="#" target="_new"><img src="/scripts/includes/images/img_fdagov_font_adj_medium.png" alt="Return font size to normal" title="Return font size to normal"/></a> <a href="#" target="_new"><img src="/scripts/includes/images/img_fdagov_font_adj_large.png" alt="Increase font size" title="Increase font size"/></a> <a href="http://www.hhs.gov/" target="_new"><img id="rrimg1" border="0" src="/scripts/includes/images/img_fdagov_hhs_masthead_logo_r.png" alt="U.S. Department of Health and Human Services" title="U.S. Department of Health and Human Services"/></a> <a href="https://www.fda.gov/" target="_new"><img src="/scripts/includes/images/gov-fda-new-white.png" alt="FDA, U.S. Food and Drug Administration" border="0" title="FDA, U.S. Food and Drug Administration"/></a> <a href="https://www.fda.gov/news-events/interactive-media" target="_new">Follow FDA</a> <a href="https://www.fda.gov/about-fda/fda-en-espanol" target="_new">En Español</a> <a href="javascript:document.getElementById('search_form').submit();" target="_new"><img src="/scripts/includes/images/img_fdagov_mast_search_button.png" alt="Search" title="Search this site"/></a> <a href="https://www.fda.gov/" target="_new"><span>Home</span></a> <a href="https://www.fda.gov/food" target="_new"><span>Food</span></a> <a href="https://www.fda.gov/Drugs" target="_new"><span>Drugs</span></a> <a href="https://www.fda.gov/Medical-Devices" target="_new"><span>Medical Devices</span></a> <a href="https://www.fda.gov/radiation-emitting-products" target="_new"><span>Radiation-Emitting Products</span></a> <a href="https://www.fda.gov/vaccines-blood-biologics" target="_new"><span>Vaccines, Blood & Biologics</span></a> <a href="https://www.fda.gov/animal-veterinary" target="_new"><span>Animal & Veterinary</span></a> <a href="https://www.fda.gov/cosmetics" target="_new"><span>Cosmetics</span></a> <a href="https://www.fda.gov/tobacco-products" target="_new"><span>Tobacco Products</span></a> <a href="javascript:window.print();" target="_new"><img src="/scripts/includes/images/img_fdagov_utility_icon_print.png" alt="Print" title="Print this page"/></a> <a href="http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain" target="_new"><img src="/scripts/includes/images/img_fdagov_utility_icon_share.png" alt="Share" title="Share this page"/></a> <a href="http://www.addthis.com/bookmark.php" target="_new"><img src="/scripts/includes/images/img_fdagov_utility_icon_email.png" alt="E-mail" title="E-mail this page"/></a> <a href="https://www.fda.gov/" target="_new">FDA Home</a> <a href="http://www.fda.gov/MedicalDevices/default.htm" target="_new">Medical Devices</a> <a href="http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/default.htm" target="_new">Databases</a> <a href="/scripts/cdrh/devicesatfda/index.cfm" target="_new"><img src="../images/supersearch.gif" align="left" border="0" alt="Super Search Devices@FDA"></a>
Current openFDA PMA Record#
- Device
- NUXFLEXXA (SODIUM HYALURONATE)
- Applicant
- Ferring Pharmaceuticals, Inc.
- PMA number
- P010029
- Supplement
- S001
- Product code
- MOZ
- Generic name
- Acid, hyaluronic, intraarticular
- Decision date
- 2006-02-27
- Decision code
- APPR
- Date received
- 2005-01-13
- Supplement type
- Normal 180 Day Track
- Approval order statement
- APPROVAL FOR 1) CHANGING THE STORAGE CONDITIONS SPECIFIED IN THE PRODUCT LABELING FROM, ?STORE IN A COLD DARK PLACE [2 ? 8 DEGREES C (36-46 DEGREES F)]. PROTECT FROM LIGHT. DO NOT FREEZE?. 2) CHANGE THE SPECIFIED SHELF LIFE TIME IN THE LABELING FORM 3 YEARS (AT REFRIGERATED TEMPERATURES) TO 12 MONTHS. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME EUFLEXXA AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN.)